Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic

The Capacity of Group V sPLA 2 to Increase Atherogenicity of ApoE −/− and LDLR −/− Mouse LDL In Vitro Predicts its Atherogenic Role In Vivo

(2009) Boris Boyanovsky et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

A-002 (Varespladib), a phospholipase A2inhibitor, reduces atherosclerosis in guinea pigs

(2009) Jose O Leite et al.   BMC Cardiovascular Disorders

Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease

(2009) Robert S. Rosenson   CARDIOVASCULAR DRUGS AND THERAPY

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

(2009) Robert S Rosenson et al.   LANCET

Site-Specific Atherogenic Gene Expression Correlates With Subsequent Variable Lesion Development in Coronary and Peripheral Vasculature

(2008) Emile R. Mohler et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Biology of Secretory Phospholipase A2

(2008) Boris B. Boyanovsky et al.   CARDIOVASCULAR DRUGS AND THERAPY

Phospholipase A2 Biochemistry

(2008) John E. Burke et al.   CARDIOVASCULAR DRUGS AND THERAPY

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

What is the future for drug development in atherosclerosis and dyslipidaemia?

(2008) Keith Suckling   Expert Opinion on Drug Discovery

Analyses of Group III Secreted Phospholipase A2Transgenic Mice Reveal Potential Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, and Atherosclerosis

(2008) Hiroyasu Sato et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The synergistic inhibition of atherogenesis in apoE−/−mice between pravastatin and the sPLA2inhibitor varespladib (A-002)

(2008) Zory Shaposhnik et al.   JOURNAL OF LIPID RESEARCH

Highly Specific and Broadly Potent Inhibitors of Mammalian Secreted Phospholipases A2

(2008) Rob C. Oslund et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent

(2008) Emile R. Mohler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

(2008) Robert L Wilensky et al.   NATURE MEDICINE

Form to function: current and future roles for atherosclerosis imaging in drug development

(2008) Alistair C. Lindsay et al.   NATURE REVIEWS DRUG DISCOVERY

Lipid signalling in disease

(2008) Matthias P. Wymann et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of secretory phospholipase A2s in human atherosclerosis development

(2007) Masayo Kimura-Matsumoto et al.   ATHEROSCLEROSIS